Last updated: February 22, 2026
What is the drug identified by NDC 50474-0804?
NDC 50474-0804 corresponds to a biologic drug, specifically Evolocumab (Repatha). It is a monoclonal antibody developed for lowering low-density lipoprotein (LDL) cholesterol. It is marketed by Amgen. The drug is approved for treatment of heterozygous familial hypercholesterolemia, homozygous familial hypercholesterolemia, and clinical atherosclerotic cardiovascular disease.
Market landscape and competitive positioning
Market size and demand
The global hypercholesterolemia market was valued at approximately $22 billion in 2021, with expected compound annual growth rate (CAGR) of 4% through 2028. The primary drivers include:
- Increasing prevalence of cardiovascular disease
- Rising awareness and diagnosis
- Adoption of biologics for lipid management
The U.S. accounts for a significant share, estimated at 40% of the global market.
Patient access and reimbursement
In the U.S., private insurers and Medicare Part D cover Evolocumab. Coverage policies permit coverage when statins are insufficient or contraindicated. Copay assistance programs and adherence rates influence market penetration.
Competition
Key competitors include:
- Alirocumab (Praluent, Regeneron/Sanofi)
- Inclisiran (Leqvio, Novartis)
- Statins (generic and branded options)
Evolocumab's differentiators are slightly lower dosing frequency and proven LDL reduction efficacy.
Patent and biosimilar status
Amgen holds market exclusivity until approximately 2032. Biosimilar competition is unlikely before 2032 due to complex manufacturing and regulatory barriers, although patent litigation may influence timing.
Price dynamics and projections
Current pricing
In the U.S., the list price for Repatha is approximately $5,850 per year for a standard prefilled pen, equating to about $487.50 per month. Actual net prices after rebates and discounts are estimated at 50-60% off list prices, translating to net prices around $2,925 to $3,510 annually.
Historical pricing trends
Since launch in 2015, prices have remained relatively stable due to patent protections and limited biosimilar competition. Slight downward adjustments occurred in response to payer negotiations and value-based pricing models.
Projected future prices
- Short-term (1–3 years): Prices likely stable, with potential moderate reductions (5-10%) driven by payer pressure and increased utilization.
- Mid-term (4–7 years): Prices may decrease 10-25% as biosimilar-like initiatives emerge, especially if generic biologics gain approval.
- Long-term (beyond 8 years): Substantial declines possible, potentially 30-50%, contingent on biosimilar entry, formulary negotiations, and technological advances in biologic manufacturing.
Factors influencing price projection
- Patent litigation outcomes: Delays or early patent invalidation could accelerate biosimilar entry.
- Regulatory environment: Changes in laws facilitating biosimilar approvals would decrease prices.
- Market penetration: Increasing adoption reduces marginal revenue per patient.
- Reimbursement policies: Shifts towards value-based models could force discounts.
Economic impact
Decreases in drug prices will influence healthcare expenditure:
| Year |
Estimated Average Price (USD) |
Notes |
| 2023 |
$4,950 – $5,850 |
Current list price stable |
| 2025 |
$4,455 – $5,265 |
Slight discounts possible |
| 2028 |
$3,300 – $4,365 |
Biosimilar competition begins |
| 2030+ |
$2,925 – $3,855 |
Significant biosimilar presence |
Summary
Evolocumab (NDC 50474-0804) will retain a premium positioning until biosimilar biologics or digital therapeutics significantly reduce costs. The anticipated price trends mirror typical biologic trajectories, with gradual reductions over the next decade, conditioned by patent litigation, biosimilar approvals, and healthcare policy adjustments.
Key Takeaways
- Current U.S. list price is approximately $5,850/year.
- Price stability expected for 1-3 years, with modest declines thereafter.
- Biosimilar competition likely by 2032, potentially halving drug costs.
- Market growth driven by increasing cardiovascular disease prevalence and adoption.
- Payer negotiations and regulatory changes are primary levers for price adjustments.
FAQs
1. When will biosimilars for Evolocumab become available?
Biosimilar approval is unlikely before 2032 due to patent protections and regulatory hurdles, but patent disputes could alter this timeline.
2. How much can prices decline as biosimilars enter the market?
Prices could decrease by 30-50% relative to current levels, depending on biosimilar market penetration and payer strategies.
3. What factors most influence Evolocumab's market share?
Pricing strategies, reimbursement policies, patent litigation outcomes, and clinical guideline recommendations.
4. Are there emerging therapies that could replace Evolocumab?
Inclisiran, a small interfering RNA (siRNA) therapy, offers similar LDL reduction with less frequent dosing, posing competition as it gains approval and market acceptance.
5. How will healthcare reimbursement policies affect future pricing?
Shift toward value-based reimbursement may reduce drug prices further through negotiated discounts and caps.
References
- IMS Health. (2021). Hypercholesterolemia Market Report.
- FDA. (2015). FDA Approval Letter for Evolocumab (Repatha).
- Amgen. (2022). Repatha Prescribing Information.
- IQVIA. (2022). Biologic & Biosimilar Market Trends.
- Market Research Future. (2022). Global Hypercholesterolemia Market Analysis.
[1] U.S. Food and Drug Administration. (2015). FDA approves Repatha to treat certain patients with high cholesterol.
